Oxular
Company Details
Status: Private
Employees: 11-50
Location:
Oxford, England, United Kingdom
Type:
sample
Technology:
sample
sample
About: “One treatment a year. Life changing.”
Oxular is developing disruptive treatments for retinal diseases. Oxular’s sustained-release formulations are engineered to last up to one year following single administration and perform in specific small spaces in the eye. This approach provides unique and precise drug distribution to tissues specifically involved in retinal diseases. Oxular’s drug administration technology is engineered to access these critical tissues through minimally invasive delivery.
This unique combination aims to substantially improve patient quality of life by increasing therapeutic effectiveness and patient safety, while reducing side-effects and minimizing the frequency of treatments. Oxular’s product development pipeline includes treatments for prevalent retinal diseases, such as diabetic macular edema, as well as rare and orphan indications, including treatments for ocular cancers.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Oxular | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.